grates as a second peak. Both lipoprotein forms of apo A-I-containing particles are present mainly in HDL, but the relative proportion of LpA-l is greater in HDL2 than in HDL3. Concentrations of LpA-l in plasma samples from normolipemic subjects average -10% higher in women than in men. The lower ape A-I concentrations in patients with significant coronary artery disease reflect a decrease in the LpA-I particles. Data obtained in octogenarians also support the possibility that LpA-l might represent the anti-atherogenic fraction of HDL. Moreover, the concentration of LpA-l in children of parents with premature coronary heart disease was lower than that of a control group without any family history of this disease. Nutrients and hypolipidemic drugs seem to affect the two kinds of particles differently.
Additional Keyphrases: sex-and age-related effects . heart disease cholesterol transport . dyslipoproteinemia Epidemiological and clinical studies showing an association between decreased concentrations of high-density-lipoprotein (HDL) cholesterol and increased risk of premature coronary artery disease (CAD) (1, 2) , have generated interest in the mechanism through which HDL prevents atherosclerosis. 3 Human HDL consists of a collection of particles differing in size, density, and apolipoprotein content (3 
Isolation and Composition of LpA-I and LpA-I:A-lI
LpA-I and LpA-I:A-il are currently purified from total plasma by sequential immunoaffinity chromatography (22, 26, 27) .
Some authors do not find any difference in lipid composition between LpA-I and LpA-I:A-il (22) , but others have claimed that the percentage of TG and the cholesteryl ester/total cholesterol ratio are lower in LpA-I than in LpA-I:A-il (27) (28) (29) . The lipid/protein ratio appears to be higher in LpA-I than in LpA-I:A-il (28) . The molar ratio of ape A-I to ape A-il in LpA-I:A-il is 1.5. Small quantities of ape A-IV, Cs, D, E are found in both fractions (30, 31) .
Of considerable significance is the finding that proteins stimulating reverse cholesterol transport (LCAT, CETP) and other proteins such as ape J are mainly present in LpA-I and not in LpA-I:A-fl (23, 30, 32) .
Physiological Role in LpA-l and LpA-I:A-II Our understanding with respect to the metabolism of ape A-I-containing particles is limited. However, Brewer et al. (28) have shown recently that both apelipeprotein particles are synthesized by the liver but that LpA-I particles are produced by the intestine only. The metabolic interrelationship between the two subpopulations is not well established, but apparently LpA-I particles are catabolized at a faster rate than are LpA-I:A-il particles (33) . One of the key questions is whether LpA-I and LpA-I:A-il have different physiological roles (34) .
To gain some insights into the mechanisms by which cholesterol movement takes place in peripheral cells, researchers have used cultured adipose cells as a model. Indeed, the fact that adipose tissue has the ability to accumulate, store, and, when needed, mobilize a large pool of unesterified cholesterol means that these cells meet the requirement for the study of reverse cholesterol transport (29) . In studies of cholesterol efflux mediated by ape A-I-containing particles in mouse adipose cells, after cholesterol preloading with low-density lipeproteins, long-term exposure to LpA-I particles promoted cholesterol efflux, whereas no efflux was observed in the presence of LpA-I:A-II (35) . These results, which emphasize that LpA-I:A-U particles behave as a distinct metabolic entity, have been confirmed in other studies (36, 37) .
The ligands that recognize the cell surface HDLbinding sites have been identified as ape A-I, ape A-N, and ape A-il (38, 39) . We proposed (39) LpA-I:A-II particles are retained in one peak and LpA-I migrates as a second peak (43) . This new system can provide specific and reproducible determinations of LpA-I in human plasma.
Clinical Significance of LpA-I and LpA-I:A-II Measurements
Coronary Artery Disease. Concentrations of LpA-I but not LpA-I:A-il were lower in normolipemic patients with angiographically documented CAD (44) than in a group of asymptomatic subjects and a group of patients with arteriographically normal coronary arteries (25) . However, in a similar study where the patient group had higher TG concentrations than the control subjects, we found that both LpA-I and LpA-I:A-il were diminished in CAD patients to a similar degree [one can postulate that the decrease in LpA-I:A-il particles in hypertriglyceridemic patients may be related to the decreased formation of such particles during lipelysis (45, 46) ]. A recent study of patients before coronary bypass surgery concluded that their concentrations of both LpA-I and LpA-I:A-II were lower than in control subjects (46) . However, discrimination analysis indicated that LpA-I was the more powerful discriminating factor in this hypertriglyceridemic population.
A case control study of ape A-I-containing particles has been performed in three populations with contrasting risks for CAD (ECTIM Study) (47 for the tested population. LpA-I and LpA-I:A-il concentrations were lower in the patients than in the control subjects, but the difference in LpA-I concentrations between the three populations was statistically significant: LpA-I for the controls and the myocardial infarction cases was much lower in Belfast than in the French centers. In this study, the multivariate analysis suggested that the LpA-I/HDL cholesterol ratio was very significant. Recently it has been also observed that the concentration of LpA-I (but not of LpA-I:A-il) in children whose parents have a premature form of CAD is lower than in a control group with no familial history of CAD (Amouyel, Isorez, Bard, Goldman, Zylberberg, and Fruchart, ms. submitted). The relevance of these observations requires further investigation. 
Longevity.

Assuming that octogenarians, who have
Dyslipoproteinemias.
Some dyslipoproteinemias have specific profiles of ape A-I particles. For instance, type ifi dyslipeproteinemia, a disorder with accelerated atherosclerosis, is characterized by a decrease of LpA-I and an increase of LpA-I:A-il (49, 50) . Non-insulin-dependent diabetes mellitus is characterized by a specific decrease in LpA-I (51) . The HDL decrease observed in patients with chronic renal failure who have to undergo hemodialysis is mainly due to a decrease in LpA-I:A-il (52) .
Diet. Diet also modifies LpA-I concentration. In a study of the effect on LpA-I of a high polyunsaturated/ saturated fatty acid ratio (53) , a ratio value of 1.1 led to a decrease in LpA-I in comparison with a ratio of 0.2. Chronic alcohol consumption was shown to lead to an increase in LpA-I:A-il, whereas LpA-I decreased ( (42) showed that LpA-I may be increased by the use of nicotinic acid, whereas probucol leads to a decrease in this particle. In contrast, nicotinic acid decreased LpA-I:A-il, and probucol had no major effect on its concentration. We have recently shown ( Table 1) that fenofibrate decreases LpA-I and increases LpA-I:Ail, whereas hydroxymethylglutaryl-CoA 
